Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

Structural and functional alterations of the vasculature may contribute to complications of hypertension. Because angiotensin II may be pivotal in some of these vascular abnormalities, we tested the hypothesis that the angiotensin type 1 (AT(1)) receptor antagonist losartan, in contrast to the beta-...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2000-04, Vol.101 (14), p.1653-1659
Main Authors: SCHIFFRIN, E. L, JEONG BAE PARK, INTENGAN, H. D, TOUYZ, R. M
Format: Article
Language:English
Subjects:
Acetylcholine - pharmacology
Adult
Angiotensin Receptor Antagonists
Antihypertensive agents
Antihypertensive Agents - therapeutic use
Arteries - drug effects
Arteries - pathology
Arteries - physiopathology
Atenolol - therapeutic use
Biological and medical sciences
Buttocks - blood supply
Cardiovascular system
Double-Blind Method
Endothelium, Vascular - physiopathology
Female
Humans
Hypertension - drug therapy
Hypertension - pathology
Hypertension - physiopathology
Losartan - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Space life sciences
Vascular Resistance
Vasodilation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Structural and functional alterations of the vasculature may contribute to complications of hypertension. Because angiotensin II may be pivotal in some of these vascular abnormalities, we tested the hypothesis that the angiotensin type 1 (AT(1)) receptor antagonist losartan, in contrast to the beta-blocker atenolol, would correct resistance artery abnormalities in patients with essential hypertension. Nineteen untreated patients with mild essential hypertension (47+/-2 years, range 30 to 65 years; 57% male) were randomly assigned in double-blind fashion to losartan or atenolol treatment for 1 year. Nine age/sex-matched normotensive subjects were also studied. Both treatments reduced blood pressure to a comparable degree (losartan, from 149+/-4.1/101+/-1.6 to 128+/-3.6/86+/-2.2 mm Hg, P
ISSN:0009-7322
1524-4539
DOI:10.1161/01.cir.101.14.1653